Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).

As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• ’Not your father’s Sandisk’: Rosenblatt starts coverage at Buy